Where is Baichuan AI headquartered?

Baichuan AI is headquartered in Beijing, China. The company has a team of 100-200 people.

What does Baichuan AI do?

Baichuan AI operates in the Foundation Models / LLMs sector. A developer of large language models (LLMs) focused on enterprise-grade generative AI solutions for the Chinese market. Delivers China-compliant large language models with a strategic pivot toward specialized AI for healthcare, offering open-source medical models (Baichuan-M3) and enterprise on-premise/cloud deployments.

When was Baichuan AI founded?

Baichuan AI was founded in 2023. It is based in Beijing, China.

Who is the CEO of Baichuan AI?

Wang Xiaochuan is the CEO of Baichuan AI. The company was founded in 2023.

Where is Baichuan AI located?

Baichuan AI is headquartered in Beijing, China.

What funding stage is Baichuan AI at?

Baichuan AI is currently at the Commercial stage.

How many employees does Baichuan AI have?

Baichuan AI has approximately 100-200 employees.

Baichuan AI

Category: Foundation Models / LLMs

A developer of large language models (LLMs) focused on enterprise-grade generative AI solutions for the Chinese market. Baichuan AI was founded in 2023. The company is led by Wang Xiaochuan. Based in Beijing, China. Team size: 100-200. Total funding raised: ~$1.04B. Latest round: Series A-II - approx. $691M (July 2024). Key investors include Alibaba, Tencent, Xiaomi, China International Capital Corporation (CICC), Shenzhen Capital Group.

Founded: 2023
Headquarters: Beijing, China
Team size: 100-200
Total funding: ~$1.04B

Value proposition

Delivers China-compliant large language models with a strategic pivot toward specialized AI for healthcare, offering open-source medical models (Baichuan-M3) and enterprise on-premise/cloud deployments.

Products and solutions

Baichuan LLM Series: Foundation models including Baichuan 4 and Baichuan 4 Turbo., Baichuan4-Finance: Domain-enhanced financial LLM released Dec 2024, surpassing GPT-4o on financial benchmarks., Baichuan-M3 / M3 Plus: Open-source medical LLM family launched Feb 2026, outperforming GPT-5.2 on HealthBench/ScanBench medical evaluations., Enterprise Solutions: Secure API access and on-premise/private cloud deployment., Developer Tools: SDKs and APIs for integration.

Unique value

Led by a proven entrepreneur (Wang Xiaochuan), focuses on 'China-native' models that understand local context and culture, and emphasizes regulatory compliance and data sovereignty.

Target customer

Large enterprises in finance, government agencies, and healthcare providers requiring secure and private LLM deployments within China.

Industries served

Healthcare (primary focus), Government/Public Sector, Telecommunications

Technology advantage

Proprietary training datasets with high-quality Mandarin content, advanced model compression techniques for efficient deployment, and a focus on long-context window models.

How they differentiate

Positions itself between large, less agile incumbents like Baidu and open-source focused players by offering premium, enterprise-ready solutions with strong commercial support and regulatory assurance.

Main competitors

Moonshot AI, Baidu ERNIE, Zhipu AI, DeepSeek

Key partnerships

Beijing Children's Hospital (AI pediatrician partnership), Beijing Municipal Government, Shanghai Municipal Government, Chinese telecom operators

Notable customers

Beijing Children's Hospital, State Grid Corporation of China

Major milestones

Became one of the first startups to receive government approval for public LLM release (August 2023)., Achieved unicorn status with a valuation over $1B within months of founding (October 2023), later reaching over $2.7B (July 2024)., Released Baichuan 4, ranking higher than GPT-4 on key Chinese language benchmarks (May 2024)., Launched Baichuan4-Finance, surpassing GPT-4o on financial benchmarks (Dec 2024)., Pivoted to healthcare AI; dissolved B2B financial services unit amid internal restructuring, cutting team from ~450 to under 200 (Mar 2025)., Launched Baichuan-M3 open-source medical LLM, outperforming GPT-5.2 and human doctors on HealthBench/ScanBench benchmarks; M3 Plus followed shortly after (Feb 2026)., CEO Wang Xiaochuan announced plans to initiate IPO in 2027 (Jan 2026)., All five co-founders departed amid disagreement over the all-in medical AI pivot, culminating in Ru Liyun's exit (Jul 2026) — Wang Xiaochuan now the sole remaining co-founder.

Growth metrics

Team grew from a small core to over 80 employees in its first year; secured pilot projects with major state-owned enterprises.

Market positioning

A leading 'AI Tiger' in China, positioned as a premium enterprise-ready provider with strong technical performance and regulatory compliance.

Geographic focus

Mainland China

Patents and IP

Information not publicly available; intellectual property is primarily in proprietary training data, model architectures, and fine-tuning pipelines.

About Wang Xiaochuan

Founder and CEO of Baichuan AI. Previously founder and CEO of Sogou (China's second-largest search engine) which went public on NYSE in 2017 and was acquired by Tencent in 2021 for $3.5B. Holds Bachelors and Masters in CS from Tsinghua University. Served on Chinese People's Political Consultative Conference (2018-2023). Named to TIME 100 Most Influential People in AI (2024).

More Foundation Models / LLMs companies

Official website: https://www.baichuan-ai.com/